115 related articles for article (PubMed ID: 1912374)
1. Effects of ubenimex, a biological response modifier, on myelodysplastic syndrome and chronic leukemia.
Tatsumi N; Sannomiya Y; Sasaki A; Im T; Ota K; Oohira H; Nakao H; Yasui Y
Biomed Pharmacother; 1991; 45(2-3):95-103. PubMed ID: 1912374
[TBL] [Abstract][Full Text] [Related]
2. Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
Kanamori H; Takasaki H; Takabayashi M; Yamaji S; Koharazawa H; Fujimaki K; Taguchi J; Ishigatsubo Y
Anticancer Drugs; 2004 Aug; 15(7):729-31. PubMed ID: 15269606
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome.
Ueda T; Tohyama K; Wano Y; Tsutani H; Fukushima T; Iwasaki H; Urasaki Y; Gotoh N; Kimura S; Okumura E
Anticancer Res; 1994; 14(5B):2093-7. PubMed ID: 7840505
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
[TBL] [Abstract][Full Text] [Related]
5. Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Usuka Y; Saito Y
Biomed Pharmacother; 1991; 45(2-3):87-93. PubMed ID: 1912373
[TBL] [Abstract][Full Text] [Related]
6. [Myelodysplastic syndrome associated with marked eosinophilia and basophilia].
Tanabe J; Sasaki S; Tamura T; Okamoto R; Sugamura R; Fujita H; Fukawa H; Kanamori H; Matsuzaki M; Mohri H
Rinsho Ketsueki; 1992 Feb; 33(2):189-93. PubMed ID: 1635167
[TBL] [Abstract][Full Text] [Related]
7. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
8. Treatment of myelodysplastic syndromes with orally administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex).
Fukutani H; Naoe T; Saito H; Ohshima T; Omine M; Miura Y; Mizoguchi H; Kimura I; Tomonaga M; Ohno R
Jpn J Clin Oncol; 1991 Aug; 21(4):287-92. PubMed ID: 1942558
[TBL] [Abstract][Full Text] [Related]
9. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
10. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
[TBL] [Abstract][Full Text] [Related]
11. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
[TBL] [Abstract][Full Text] [Related]
12. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of chronic adult T-cell leukemia with ubenimex.
Okamura T; Shibuya T; Harada M; Niho Y
Acta Haematol; 1992; 87(1-2):94-7. PubMed ID: 1350160
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
Sun JF; Yang B; Zhang L; Huang Y; Yang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
[TBL] [Abstract][Full Text] [Related]
15. Bestatin treatment of myelodysplastic syndromes (MDS) and the effects of bestatin on hematopoiesis in MDS.
Uzuka Y; Saito Y
Acta Oncol; 1990; 29(6):803-7. PubMed ID: 2223153
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
17. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
19. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
20. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
